Azilsartan KaMedoxoMil CAS 863031-24-7

Pwodwi Deskripsyon:

Non pwodwi: Azilsartan kaMedoxoMil CAS NON: 863031-24-7

 

Sinonim:

1H-Benzimidazole-7-7-kaboksilik asid, 1-(2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) (1,1'-biphenyl) -4-yl) methyl) -2-ethoxy-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester, sel potasyom;

Azilsartan medoxomil monopotassium;

potasyom, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl2-ethoxy-3-[4-[4-2-(5-oxo-1-oksa-2-aza-4-azanidacycyclopent-2-en-3-yl)fizyl] methyl] benzimidazole-4-kaboksilate;

 

Chimik & Pwopriyete fizik:

Aparans: Blan oswa poud blan

Assay: ≥99.00%

Dlo Solibilite: Ensolubl

Soluble: DMSO, Methanol

 

Azilsartan kamedoxomil, te devlope pa Pranda famasetik, te apwouve pou tretman an nan hypertansyon ak te lanse nan peyi Etazini anba non an mak Edarbi. Edarbi se yon prodrug ki sibi idrolysis rapid libere azilsartan, engredyan aktif la (TAK-536, 39). Kom 8th récepteurs (ARB) antre nan mache mondyal la, azilsartan kamedoxomil ka fonksyone kom monoterapi oswa nan konbinezon ak lot ajan antihypertensive. Nan plizye syans klinik, azilsartan monotherapeutic kamedoxomil te montre siperye antihypertensive ak yon pwofil sekirite favorab / tolerabilite nan pasyan konpare ak lot etabli terapetik, ki gen ladan valsartan, medoxomil olmesartan, candesartan, ak telmisartan. Nan fen 2011, Pranda te anonse ke FDA tou te apwouve tablet konbinezon fiks-doz nan azilsartan kamedoxomil ak chlorthalidone anba non an komes nan Edarbyclor.

 

Si ou enterese nan pwodwi nou yo oswa ou gen nenpot kesyon, tanpri santi yo lib yo kontakte nou!

 

Pwodwi anba patant yo ofri pou R & D rezon selman. Sepandan, denye responsablite a bay manti selman ak achte a.

Baj popilè: azilsartan kamedoxomil cas 863031-24-7, manifaktire, founise, faktori, achte, nan stock

• On: EFONIDIPIN CAS 111011-76-8
• Pwochen: Bosentan Hydrate CAS 157212-55-0